{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T22:09:46Z","timestamp":1649196586514},"reference-count":23,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2019,4,30]]},"DOI":"10.5582\/bst.2019.01072","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T18:02:33Z","timestamp":1556042553000},"page":"189-196","source":"Crossref","is-referenced-by-count":1,"title":["A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: a preliminary study"],"prefix":"10.5582","volume":"13","author":[{"given":"Sho","family":"Kiritani","sequence":"first","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Arita","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumihito","family":"Tamura","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Kokudo","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, Caballeria J, Rodes J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987; 7:122-128.","DOI":"10.1002\/hep.1840070124"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013; 38:584-595.","DOI":"10.1111\/apt.12427"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006; 55 Suppl 6:vi1-12.","DOI":"10.1136\/gut.2006.099580"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Angeli P, Gin\u00e8s P, Wong F, <i>et al<\/i>. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015; 64:531-537.","DOI":"10.1136\/gutjnl-2014-308874"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet. 2008; 371:1624-1632.","DOI":"10.1016\/S0140-6736(08)60695-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K; ASCITES Clinical Pharmacology Group. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res. 2012; 40:2381-2393.","DOI":"10.1177\/030006051204000637"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Okita K, Kawazoe S, Hasebe C, Kajimura K, Kaneko A, Okada M, Sakaida I; ASCITES Dose-Finding Trial Group. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014; 44:83-91.","DOI":"10.1111\/hepr.12099"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367:2407-2418.","DOI":"10.1056\/NEJMoa1205511"},{"key":"9","unstructured":"9. FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. <i>https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm350062.htm<\/i> (accessd April 14, 2019)"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, Okada M, Okita K; ASCITES-DOUBLEBLIND Study Group. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014; 44:73-82.","DOI":"10.1111\/hepr.12098"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013; 57:1651-1653.","DOI":"10.1002\/hep.26359"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: Analysis of clinical trials database. Drug Saf. 2015; 38:1103-1113.","DOI":"10.1007\/s40264-015-0327-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53:397-417.","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23:164-176.","DOI":"10.1002\/hep.510230122"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fukui H, Saito H, Ueno Y, <i>et al<\/i>. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016; 51:629-650.","DOI":"10.1007\/s00535-016-1216-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. D&apos;Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986; 31:468-475.","DOI":"10.1007\/BF01320309"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cardenas A, Gines P. Management of patients with cirrhosis awaiting liver transplantation. Gut. 2011; 60:412-421.","DOI":"10.1136\/gut.2009.179937"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl. 2011; 17:129-136.","DOI":"10.1002\/lt.22218"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. D&apos;Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 2006; 44:217-231.","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Panos MZ, Moore K, Vlavianos P, Chambers JB, Anderson JV, Gimson AE, Slater JD, Rees LH, Westaby D, Williams R. Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size. Hepatology. 1990; 11:662-667.","DOI":"10.1002\/hep.1840110420"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hirai K, Shimomura T, Moriwaki H, Ishii H, Shimoshikiryo T, Tsuji D, Inoue K, Kadoiri T, Itoh K. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. Eur J Clin Pharmacol. 2016; 72:1177-1183.","DOI":"10.1007\/s00228-016-2091-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res. 2013; 41:835-847.","DOI":"10.1177\/0300060513480089"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sakaida I, Terai S, Kurosaki M, Yasuda M, Okada M, Bando K, Fukuta Y. Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study). Hepatol Res. 2017; 47:1137-1146.","DOI":"10.1111\/hepr.12852"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/13\/2\/13_2019.01072\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T23:21:56Z","timestamp":1558135316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/13\/2\/13_2019.01072\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2019.01072","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]}}}